Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MPL | P40238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902973 | 1.00 | HTR7 (0.33) | HTR7GRM2HTR1ASLC6A2SLC6A3 | |
| SCHEMBL9902651 | 0.79 | HTR7 (0.35) | HTR7GRM2HTR1A | |
| SCHEMBL9903245 | 0.79 | HTR7 (0.35) | HTR7GRM2HTR1A | |
| SCHEMBL9903595 | 0.72 | GRM2 (0.38) | GRM2 | |
| SCHEMBL9903453 | 0.70 | — | — | |
| SCHEMBL9903555 | 0.70 | — | — | |
| SCHEMBL9901702 | 0.70 | — | — | |
| SCHEMBL9903244 | 0.70 | — | — | |
| SCHEMBL9902326 | 0.68 | — | — | |
| SCHEMBL9903744 | 0.67 | BRD4 (0.40) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916549-B2 | Thienooxazepine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8916549-B2 | Thienooxazepine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8916549-B2 | Thienooxazepine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2463290-B1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2463290-B1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-2463290-A1 | THIENOOXAZEPINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
| EP-2463290-A1 | THIENOOXAZEPINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011016459-A1 | THIENOOXAZEPINE DERIVATIVE | 武田薬品工業株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | HTR2C, HTR2B, HTR2A | HTR7 10/4885GRM2 147/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.